Bright Minds Biosciences Inc.
CAValuation Metrics
Bright Minds Biosciences Inc.'s Market Cap is $256M. At end of 2025 it was $606M. Ranked #2709 of 3,116 in US market (top 87%), #1176 of 1,472 on NASDAQ (top 80%), #213 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $256M | US#2,709/3,116 Sec#213/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-18M | US—/3,116 Sec—/265 |
| Total Assets | $223M | US#2,966/3,116 Sec#239/265 |
| Net Assets | $222M | US#2,635/3,116 Sec#177/265 |
| Employees | 26 | US#2,745/3,116 Sec#218/265 |
| Value | ||
| P/B | 1.15x | US#1,541/3,116 Sec#78/265 |
| FCF Yield | -6.99% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -7.99% | US#2,319/3,116 Sec#77/265 |
| ROA | -7.93% | US#2,609/3,116 Sec#97/265 |
| Financial Health | ||
| Debt Ratio | 0.83% | US#8/3,116 Sec#1/265 |
| Total Debt | $47208.00 | US#3,008/3,116 Sec#259/265 |
| FCF | $-18M | US#2,404/3,116 Sec#91/265 |
| Cash | $221M | US#1,650/3,116 Sec#100/265 |
| Current Ratio | 121.97x | US#31/3,116 Sec#1/265 |
| Performance | ||
| 1Y Return | -52.26% | US#1,663/3,116 Sec#141/265 |
| 1M Return | -48.43% | US#450/3,116 Sec#34/265 |
| From 52W High | -78.88% | US#2,752/3,116 Sec#213/265 |
| 1Y MDD | -72.77% | US#2,387/3,116 Sec#157/265 |
| Trading | ||
| Volume | 1,753,824 shares | US#3,018/3,116 Sec#262/265 |
| Trading Value | $44M | US#2,752/3,116 Sec#224/265 |
| Per Share | ||
| EPS | $-1.81 | US—/3,116 Sec—/265 |
| BPS | $22.64 | US#1,123/3,116 Sec#24/265 |
Company Info
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.